Targeted Bevacizumab Therapy for Recurrent Vocal Fold Hemorrhage: First Case Report.

LaryngoscopeMay 11, 2026 (epub)
Case ReportOtolaryngology (ENT)

Andrés Lanas Volz, Camila Ramírez Pelayo

✦ AI-curated · Sources linked

Case in brief

A patient with recurrent vocal fold hemorrhage, unresponsive to standard treatments, was treated with targeted intracordal bevacizumab therapy. This intervention led to the resolution of hemorrhagic episodes and sustained clinical improvement during follow-up, indicating a promising alternative for managing this condition.

Diagnostic / clinical pearl

Targeted bevacizumab therapy may be considered for patients with recurrent vocal fold hemorrhage that does not respond to conventional treatments.

Why it matters

This case highlights the potential of antiangiogenic therapy in managing challenging cases of vocal fold hemorrhage, expanding treatment options for clinicians.

Source

PubMed · PMID 42116713

Published in Laryngoscope. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.